Article Text

Download PDFPDF
Contributing Factors for Bone Metastasis in Uterine Cervical Cancer
  1. Aera Yoon, MD,
  2. Chel Hun Choi, MD,
  3. Ha-Jeong Kim, MD,
  4. Jin-Young Park, MD,
  5. Yoo-Young Lee, MD, PhD,
  6. Tae-Joong Kim, MD,
  7. Jeong-Won Lee, MD, PhD,
  8. Duk-Soo Bae, MD, PhD and
  9. Byoung-Gie Kim, MD, PhD
  1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  1. Address correspondence and reprint requests to Byoung-Gie Kim, MD, PhD, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine,81 Irwon-Ro, Gangnam-gu, Seoul, 135-710, Korea. E-mail: bgkim{at}skku.edu.

Abstract

Objective The purpose of this study was to describe the clinical characteristics and to assess the contributing factors in patients developing bone metastasis in uterine cervical cancer.

Methods Two thousand thirteen patients had a diagnosis of uterine cervical cancer at Samsung Medical Center between June 1994 and December 2011. During the study period, 105 patients with bone metastasis were identified, and their clinicopathologic data were investigated retrospectively.

Results Among 105 patients with bone metastasis, 14 patients were excluded and 91 patients were evaluable. The median bone metastasis–free survival was 27 months (range, 0–279 months).

The time to bone metastasis was significantly shorter in patients with adenocarcinoma than in patients with squamous cell carcinoma (median duration, 12 vs 29 months; P = 0.016). In addition, it was shorter in patients with stage IIB to stage IV disease than in those with stage I to stage IIA disease (15 vs 22 months; P = 0.02). The median survival after bone metastasis was 10 months, longer in the patients who received radiotherapy (± chemotherapy) than in the patients who received chemotherapy alone as a salvage therapy (12 vs 7 months; P = 0.01). Initial stage, number of bone metastases, location of involved bone, and coexisting metastatic lesion were not associated with the overall survival of the patients.

Conclusions Our study demonstrates that adenocarcinoma, advanced stage (IIB-IV) and initial multiple bone metastases contribute to earlier bone metastasis. Once bone metastasis was recognized, the survival of these patients was poor and no factors were identified to predict survival of those patients.

  • Adenocarcinoma
  • Bone metastasis
  • Contributing factor
  • Uterine cervical cancer

Statistics from Altmetric.com

Footnotes

  • Aera Yoon and Chel Hun Choi contributed equally to this work.

  • The authors did not received funding for this work.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.